Beam Therapeutics Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:BEAM) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 1.47 B1.39 B1.31 B1.48 B1.48 B Total liabilities 343.78 M344.34 M345.08 M242.82 M316.36 M Total equity 1.12 B1.05 B966 M1.24 B1.16 B Total liabilities & shareholders' equities 1.47 B1.39 B1.31 B1.48 B1.48 B Total debt ————100.19 M Net debt ————-1.1 B

News

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle

Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX)

The Disinflation Trade Has A New Address: Genomics

Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM)

BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria

Beam Therapeutics Stock Soars 21% in Three Months: Here's Why

Cathie Wood Sells $12.3M in Archer Aviation Stock (ACHR). Here Are Her Latest Trades - TipRanks.com

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow (NASDAQ:BEAM) 2026-05-20